Ensuring Successful Technology Transfer In ADC Development

Technology transfers can introduce risk and create knowledge gaps at every stage of development, whether it’s moving a process from development to manufacturing, transferring methods between analytical labs, or onboarding a new CDMO partner. This is especially true in the development of antibody-drug conjugates (ADC), where the complexity of conjugation processes, analytical characterization, and specialized manufacturing expertise is often distributed across multiple CDMO partners.

Join Bioprocess Online’s Tyler Menichiello for an interactive panel discussion with Sourav Kundu, Ph.D., senior vice president of development and manufacturing at NextCure, and Will Olughu, Ph.D., global CMC lead and senior principal scientist at Ipsen, as they explore practical ways to navigate the transfer of process and analytical knowledge in ADC development to reduce risk and avoid delays.